Medtronic Care - HF

 

Medtronic

Indications, contraindications, warnings, precautions, and adverse events

Privacy Statement
Terms of Use

Study Results

The landmark CARE-HF trial shows that Medtronic CRT on top of optimal medical therapy improves symptoms and reduces morbidity and all-cause mortality in moderate to severe heart failure patients with low ejection fraction and left ventricular systolic dysfunction.

Study results

CRT Reduces Mortality and Cardiovascular Hospitalizations

Primary endpoint: all-cause mortality or unplanned cardiovascular hospitalization

Secondary endpoint: all-cause mortality

  • CRT devices provide sustained reduction in combined all-cause mortality and cardiovascular hospitalization.
  • In combination with optimal medical therapy (OMT), CRT is superior to OMT alone.

CRT Improves Cardiac Function and Structure

Medtronic CRT devices reduce the degree of ventricular dyssynchrony and deliver a sustained improvement in cardiac function and structure.1-3

CRT Improves Cardiac Function and Structure

CRT Improves Symptoms and Quality of Life

  Medical
Therapy Alone
(N=404) 		Medical Therapy
plus Cardiac
Resynchronization
(N=409)		 Difference
in Means
(95% CI)
Continuous outcome   (value at 90 days)
NYHA Class 2.7±0.9 2.1±1.0 0.6 (0.4 to 0.7)
Minnesota Living with
Heart Failure score1		 40±22 31±22 -10 (-8 to -12)
EuroQoL EQ-5D score2 0.63±0.29 0.70±0.28 0.08 (0.04 to 0.12)
References
  1. Scores on the Minnesota Living with Heart failure questionnaire range from 0 to 150, with scores reflecting a poorer quality of life
  2. Scores on the European Quality of Life-5 Dimensions (EuroQol. EQ-5D) instrument range from -0.594 to 1.000, with 1.000 indicating fully healthy and 0 dead.